1. Home
  2. How CGM Works

Discover the easy-to-use*†1,2
FreeStyle Libre CGM systems

Introduce your patients to better glucose management*†‡1-4

The FreeStyle Libre portfolio of products offers a seamless diabetes management experience. With these CGM systems, patients experience fewer complications and reduced resource utilization*†1-3,5-9.

 

CGM = continuous glucose monitoring

Sensors designed with patients in mind

  • Small, discreet10, and easy for patients*†1,2

  • Helps patients understand how food, activity and medication impacts their glucose levels11

  • Easily applied*†1,2,10 to the back of the upper arm for up to 14 days12-14 

  • Water-resistant§

  • Minute-to-minute readings12-14

FreeStyle Libre sensor

The FreeStyle Libre 3 system

  • Easy-to-share resultsII¶10 to help inform patient care

  • Minute-to-minute glucose readings that stream directly to your patients’ smartphones# or reader** so they can act faster to avoid hypoglycemia

  • Readings updated 5x faster than other CGM systems15

The FreeStyle Libre 2 system

  • Patient data easily†† accessible to the patient's entire care team on the FreeStyle Libre 2 app‡‡

  • Real-time glucose readings13 and feedback on glucose levels and trends to support informed diabetes management decisions

  • Freedom for patients to view their glucose readings by scanning their sensor using their smartphone‡‡ or reader§§

  • Ability to receive insights and reports with glucose patterns and trends all in one app‡‡

 

LibreView

Easily connect with your patients through LibreViewIIII. With LibreView, your patients’ glucose data#‡‡ can be automaticallyII¶ uploaded to a secure¶¶ cloud-based systemIIII where you can access reports about glucose patterns and trends.

The CGM difference

With the FreeStyle Libre CGM systems, your patient’s sensor measures glucose every minute12-14 so they can dose insulin or treat for lows. And instead of time-consuming interpretations of blood glucose logs, sensor data quickly identifies glycemic patterns and trends¶¶11.

No confirmatory fingersticks***††† required for insulin dosing—even when glucose is low, falling, or rapidly changing12-14.

Discover the difference
between CGM sensor and blood glucose readings

FreeStyle Libre 2 and FreeStyle Libre 3 systems are indicated for use in people with diabetes age 4 and older.

Medicare coverage is available for FreeStyle Libre systems if their respective readers are used to review glucose data on some days every month. Medicare and other third-party payor criteria apply.

Abbott provides this information as a courtesy, it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.

* Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore, the study data is applicable to both products.

† Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore, the study data is applicable to both products.

‡ Compared to self-monitoring blood glucose testing.

§ Sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.

II The FreeStyle Libre 3 app is designed to facilitate data sharing between patients and their healthcare providers and caregivers. 

¶ The user must be connected to data services for glucose data to automatically upload to LibreView. 

# The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app.

** The FreeStyle Libre 3 app and the FreeStyle Libre 3 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.

†† In comparison to the FreeStyle Libre 2 reader.

‡‡ The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app. Use of the FreeStyle Libre 2 app requires registration with LibreView.

§§ The FreeStyle Libre 2 app and the FreeStyle Libre 2 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.

IIII The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.

¶¶ LibreView is ISO27001/27018/27701 certified and HITRUST CSF Certified.

## Data from this study was collected with the US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore, the study data is applicable to both products.

*** FreeStyle Libre 2 and 3 systems: Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first 12 hours.

††† FreeStyle Libre 14 day system: Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.

References: 1. Haak, Thomas, et al. "Flash Glucose-sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-treated Type 2 Diabetes: a Multicentre, Open-label Randomised Controlled Trial." Diabetes Therapy 8, no. 1 (2017): 55-73. https://doi.org/10.1007/s13300-016-0223-6. 2. Campbell, Fiona M., et al. "Outcomes of Using Flash Glucose Monitoring technology by Children and young people with Type 1 Diabetes in a Single Arm Study." Pediatric Diabetes 19, no. 7 (2018): 1294-1301. https://doi.org/10.1111/pedi.12735. 3. Bolinder, Jan, et al. "Novel Glucose-sensing Technology and Hypoglycaemia in Type 1 Diabetes: a Multicentre, Non-masked, Randomised Controlled Trial." The Lancet 10057, no. 388 (2016): ‍2254-2263. https://doi.org/10.1016/S0140-6736(16)31535-5. 4. Yaron, Marianna, et al. "Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes." Diabetes Care 42, no. 7 (2019); 1178-1184. https://doi.org/10.2337/dc18-0166. 5. Evans, Mark, et al. "The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: A Meta-Analysis of Clinical Trials and Real-World Observational Studies." Diabetes Therapy 11, no. 1 (2020): 83-95. https://doi.org/10.1007/s13300-019-00720-0. 6. Kroger, Jens, et al. "Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults With Type 2 Diabetes." Diabetes Therapy 11, no. 1 (2020): 271-291. https://doi.org/10.1007/s13300-019-00741-9. 7. Dunn, Timothy C., et al. “Real-World Flash Glucose Monitoring Patterns and Associations Between Self-Monitoring Frequency and Glycaemic Measures: A European Analysis of Over 60 Million Glucose Tests.” Diabetes Research and Clinical Practice 137 (2018): 37-46. https://doi.org/10.1016/j.diabres.2017.12.015. 8. Fokkert, Marion, et al. “Improved Well-Being and Decreased Disease Burden After 1-Year Use of Flash Glucose Monitoring (FLARE-NL4).” BMJ Open Diabetes Research & Care 7, no. 1 (2019): e000809. https://doi.org/10.1136/bmjdrc-2019-000809. 9. Charleer, Sara, et al. “Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study.” Diabetes Care 43, no. 2 (2020): 389-397. https://doi.org/10.2337/dc19-1610. 10. Data on File. Abbott Diabetes Care. 11. Unger, Jeff, et al. "Practical guidance for using the FreeStyle Libre flash continuous glucose monitoring in primary care." Postgraduate Medicine 132, no 4. (2020): 305-313. https://doi.org/10.1080/00325481.2020.1744393. 12. FreeStyle Libre 14 day User's Manual. 13. FreeStyle Libre 2 User's Manual. 14. FreeStyle Libre 3 User's Manual. 15. Dexcom G6 CGM User Guide, Dexcom G7 CGM User Guide and Medtronic Guardian Connect System User Guide.

ADC-42702 v3.0

Important Safety Information

FreeStyle Libre 14 day, FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855‑632‑8658 or FreeStyleLibre.us for safety info.

The product images are for illustrative purposes only.

The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.

No use of any Abbott trademark, trade name, or trade dress in this site may be made without prior written authorization of Abbott Laboratories, except to identify the product or services of the company.

This website and the information contained herein is intended for use by residents of the United States.

ADC-45115 v19.0